Mira1a Therapeutics, Inc. — Form D
Mira1a Therapeutics, Inc. of BALTIMORE, MD, a company, filed a Form D exempt-offering notice with the SEC on 2022-08-01. The offering totals $6.5M, of which $6.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-08-01
- Form: D
- Accession: 0001904286-22-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $6.5M
- Amount sold: $6.5M
- Investors: 76
- Date of first sale: 2021-11-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-454387
Issuer
- Name: Mira1a Therapeutics, Inc.
- CIK: 0001904286
- Entity type: Corporation
- Jurisdiction: FLORIDA
- Incorporated: 2020
- Address: 855 N WOLFE STREET #601, BALTIMORE, MD, 21205
- Phone: 813-864-2562
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Jude Uzonwanne | Executive Officer | BALTIMORE, MD |
| Paul Rivard, ESQ | Executive Officer | Baltimore, MD |
| Chris Chapman, MD | Director | Baltimore, MD |
| Brad Kroenig | Director | Baltimore, MD |
| James McNulty, CPA | Executive Officer | Baltimore, MD |
| Hugh McColl III | Director | Baltimore, MD |
| Talhia Tuck, JD | Director | Baltimore, MD |
| Josh Silverman | Director | Baltimore, MD |
| Dave Vorhoff | Director | Baltimore, MD |
| Adam Kaplin, MD, PhD | Executive Officer | Baltimore, MD |
Other filings by this issuer (1)
More